All co-culture formats are tailored to probe specific questions related to cell killing, suppression, signaling, or hematopoietic resilience under immune pressure.
Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
As immune effector cell (IEC) therapies evolve in complexity and potency, new layers of safety concerns emerge—particularly in relation to their impact on the hematopoietic compartment. Among these, Immune Effector Cell-associated Hematotoxicity (ICAHT) represents a distinct, mechanism-driven toxicity that goes beyond acute inflammatory responses. Unlike cytokine-driven toxicities, ICAHT often reflects a combination of direct cytotoxicity, sustained immune pressure, and paracrine disruption of the bone marrow niche, leading to suppressed hematopoietic recovery.
To dissect these multifactorial effects, co-culture systems have emerged as a gold-standard platform to simulate the physiological interface between IECs and blood-forming cells. Creative Biolabs has developed a dedicated Co-Culture System based Immune Cell and Blood Cell Interaction Analysis Service to capture, quantify, and analyze these interactions with resolution and reproducibility. This service forms a core module of our broader ICAHT Management Solutions platform.
Our co-culture platform is designed to emulate both contact-dependent and soluble factor–mediated interactions between immune effector cells and hematopoietic targets. By establishing defined microenvironments in which IECs such as CAR-T, CAR-NK, or TCR-modified cells are exposed to CD34⁺ hematopoietic stem/progenitor cells (HSPCs), lineage-committed progenitors, or supportive stromal components, we help researchers simulate and monitor the suppressive and cytotoxic effects that IECs may exert on hematopoietic populations.
We offer multiple customizable co-culture formats, including:
Assays can be performed under static or dynamic conditions, and readouts include functional, phenotypic, and secretory data layers to enable comprehensive mechanistic insights.
We support IECs derived from cell lines, primary donors, or engineered constructs (e.g., CAR constructs provided by clients), as well as hematopoietic targets from cord blood, bone marrow, or mobilized peripheral blood.
Our co-culture assays are coupled with:
Conditioned media from co-cultures are analyzed using high-sensitivity cytokine detection platforms to quantify key inflammatory and suppressive mediators including IFN-γ, TNF-α, GM-CSF, IL-1β, and TGF-β.
We offer side-by-side comparisons of different IEC designs (e.g., CD28 vs 4-1BB co-stimulation) to support construct optimization, safety ranking, and functional de-risking at early stages of development.
All co-culture formats are tailored to probe specific questions related to cell killing, suppression, signaling, or hematopoietic resilience under immune pressure.
Compatible with a wide range of IEC formats and preclinical models, allowing custom construct testing across varying target cell types and conditions.
Use of primary human hematopoietic cells and clinically relevant culture conditions ensures translational value.
Co-culture results can be linked to transcriptomic or proteomic profiling of surviving or suppressed hematopoietic populations upon request.
Time-course studies, varied effector-to-target (E:T) ratios, and isotype or unmodified cell controls are available to refine interpretability.
Q1: Can I provide my own CAR-T or CAR-NK cells for testing?
A1: Yes, we welcome client-supplied IECs for co-culture testing. We also offer internal generation and expansion services if needed.
Q2: Can cytokine blockade or inhibition strategies be incorporated?
A2: Absolutely. We can include neutralizing antibodies or small-molecule inhibitors to study pathway-specific mitigation strategies.
Creative Biolabs is dedicated to empowering translational researchers and cell therapy developers with advanced tools to assess and mitigate immune-mediated hematopoietic risk. Our Co-Culture System based Immune Cell and Blood Cell Interaction Analysis Service offers a flexible, high-fidelity window into one of the most critical and understudied aspects of immune effector biology.
We invite you to collaborate with our scientific team to design a customized co-culture assay that matches your construct, hypothesis, and safety concerns. Whether you are in early discovery or advanced preclinical optimization, we are ready to support your goals with precision and partnership.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
